Predictors of early disease recurrence following hepatic resection for colorectal cancer metastasis

European Journal of Surgical Oncology

Volumn 33, Issue 8, 2007, Pages 1003-1009

  Malik, H Z ^a   Gomez, D ^a   Wong, V ^a   Al Mukthar, A ^a   Toogood, G J ^a   Lodge, J P A ^a   Prasad, K R ^a  

^a ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

Colorectal liver metastases; Early recurrence; Multiple metastases

Indexed keywords

ADULT; AGED; ARTICLE; CANCER RECURRENCE; CANCER STAGING; COLORECTAL CANCER; FEMALE; HISTOPATHOLOGY; HUMAN; LIVER METASTASIS; LIVER RESECTION; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PREDICTION; PREOPERATIVE PERIOD; PRIORITY JOURNAL; REOPERATION; SURGICAL TECHNIQUE; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; COLORECTAL NEOPLASMS; FEMALE; HEPATECTOMY; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TIME FACTORS;

EID: 34548656472     PISSN: 07487983     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejso.2007.01.005     Document Type: Article

References (52)

1. Choti M.A., Sitzmann J.V., Tiburi M.F., et al. Trends in long-term survival following liver resection for hepatic colorectal metastases. Ann Surg 235 (2002) 759-766
2. Hughes K., Scheele J., and Sugarbaker P.H. Surgery for colorectal cancer metastatic to the liver. Optimizing the results of treatment. Surg Clin North Am 69 (1989) 339-359
3. Rees M., Plant G., and Bygrave S. Late results justify resection for multiple hepatic metastases from colorectal cancer. Br J Surg 84 (1997) 1136-1140
4. Steele Jr. G., Bleday R., Mayer R.J., Lindblad A., Petrelli N., and Weaver D. A prospective evaluation of hepatic resection for colorectal carcinoma metastases to the liver: Gastrointestinal Tumor Study Group Protocol 6584. J Clin Oncol 9 (1991) 1105-1112
5. Sugihara K., Hojo K., Moriya Y., Yamasaki S., Kosuge T., and Takayama T. Pattern of recurrence after hepatic resection for colorectal metastases. Br J Surg 80 (1993) 1032-1035
6. Ohlsson B., Stenram U., and Tranberg K.G. Resection of colorectal liver metastases: 25-year experience. World J Surg 22 (1998) 268-276
7. Okano K., Yamamoto J., Kosuge T., et al. Fibrous pseudocapsule of metastatic liver tumors from colorectal carcinoma. Clinicopathologic study of 152 first resection cases. Cancer 89 (2000) 267-275
8. Scheele J., Stangl R., Altendorf-Hofmann A., and Gall F.P. Indicators of prognosis after hepatic resection for colorectal secondaries. Surgery 110 (1991) 13-29
9. Abdalla E.K., Vauthey J.N., Ellis L.M., et al. Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. Ann Surg 239 (2004) 818-825
10. Fernandez F.G., Drebin J.A., Linehan D.C., Dehdashti F., Siegel B.A., and Strasberg S.M. Five-year survival after resection of hepatic metastases from colorectal cancer in patients screened by positron emission tomography with F-18 fluorodeoxyglucose (FDG-PET). Ann Surg 240 (2004) 438-447 discussion 447-450
11. Pawlik T.M., Scoggins C.R., Zorzi D., et al. Effect of surgical margin status on survival and site of recurrence after hepatic resection for colorectal metastases. Ann Surg 241 (2005) 715-722
12. Jaffe B.M., Donegan W.L., Watson F., and Spratt Jr. J.S. Factors influencing survival in patients with untreated hepatic metastases. Surg Gynecol Obstet 127 (1968) 1-11
13. Bengmark S., and Hafstrom L. The natural history of primary and secondary malignant tumors of the liver. I. The prognosis for patients with hepatic metastases from colonic and rectal carcinoma by laparotomy. Cancer 23 (1969) 198-202
14. Douillard J.Y., Cunningham D., Roth A.D., et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 355 (2000) 1041-1047
15. Saltz L.B., Cox J.V., Blanke C., et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 343 (2000) 905-914
16. de Gramont A., Figer A., Seymour M., et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18 (2000) 2938-2947
17. Memon M.A., and Beckingham I.J. Surgical resection of colorectal liver metastases. Colorectal Dis 3 (2001) 361-373
18. Bozzetti F., Doci R., Bignami P., Morabito A., and Gennari L. Patterns of failure following surgical resection of colorectal cancer liver metastases. Rationale for a multimodal approach. Ann Surg 205 (1987) 264-270
19. Ekberg H., Tranberg K.G., Andersson R., et al. Pattern of recurrence in liver resection for colorectal secondaries. World J Surg 11 (1987) 541-547
20. Lange J.F., Leese T., Castaing D., and Bismuth H. Repeat hepatectomy for recurrent malignant tumors of the liver. Surg Gynecol Obstet 169 (1989) 119-126
21. Stone M.D., Cady B., Jenkins R.L., McDermott W.V., and Steele Jr. G.D. Surgical therapy for recurrent liver metastases from colorectal cancer. Arch Surg 125 (1990) 718-721 discussion 722
22. Couinaud C. Lobes et segments hepatiques: notes sur l'architecture anatomique et chirurgicale du foie. Presse Med 62 (1954) 709-712
23. Fong Y., Fortner J., Sun R.L., Brennan M.F., and Blumgart L.H. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg 230 (1999) 309-318 discussion 318-321
24. Imamura H., Seyama Y., Kokudo N., et al. One thousand fifty-six hepatectomies without mortality in 8 years. Arch Surg 138 (2003) 1198-1206 discussion 1206
25. Heriot A.G., and Karanjia N.D. A review of techniques for liver resection. Ann R Coll Surg Engl 84 (2002) 371-380
26. Takahashi S., Konishi M., Nakagohri T., Gotohda N., Saito N., and Kinoshita T. Short time to recurrence after hepatic resection correlates with poor prognosis in colorectal hepatic metastasis. Jpn J Clin Oncol 36 (2006) 368-375
27. Belghiti J., Hiramatsu K., Benoist S., Massault P., Sauvanet A., and Farges O. Seven hundred forty-seven hepatectomies in the 1990s: an update to evaluate the actual risk of liver resection. J Am Coll Surg 191 (2000) 38-46
28. Fortner J.G., and Blumgart L.H. A historic perspective of liver surgery for tumors at the end of the millennium. J Am Coll Surg 193 (2001) 210-222
29. Jarnagin W.R., Gonen M., Fong Y., et al. Improvement in perioperative outcome after hepatic resection: analysis of 1,803 consecutive cases over the past decade. Ann Surg 236 (2002) 397-406
30. Kemeny N., Jarnagin W., Paty P., et al. Phase I trial of systemic oxaliplatin combination chemotherapy with hepatic arterial infusion in patients with unresectable liver metastases from colorectal cancer. J Clin Oncol 23 (2005) 4888-4896
31. Bismuth H., Adam R., Levi F., et al. Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy. Ann Surg 224 (1996) 509-520
32. Giacchetti S., Itzhaki M., Gruia G., et al. Long-term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery. Ann Oncol 10 (1999) 663-669
33. Adam R., Avisar E., Ariche A., et al. Five-year survival following hepatic resection after neoadjuvant therapy for nonresectable colorectal. Ann Surg Oncol 8 (2001) 347-353
34. Fernandez F.G., Ritter J., Goodwin J.W., Linehan D.C., Hawkins W.G., and Strasberg S.M. Effect of steatohepatitis associated with irinotecan or oxaliplatin pretreatment on resectability of hepatic colorectal metastases. J Am Coll Surg 200 (2005) 845-853
35. Vauthey J.N., Pawlik T.M., Ribero D., et al. Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol 24 (2006) 2065-2072
36. Chang A.E., Schneider P.D., Sugarbaker P.H., Simpson C., Culnane M., and Steinberg S.M. A prospective randomized trial of regional versus systemic continuous 5-fluorodeoxyuridine chemotherapy in the treatment of colorectal liver metastases. Ann Surg 206 (1987) 685-693
37. Cunningham D., Pyrhonen S., James R.D., et al. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 352 (1998) 1413-1418
38. Tanaka K., Shimada H., Miura M., et al. Metastatic tumor doubling time: most important prehepatectomy predictor of survival and nonrecurrence of hepatic colorectal cancer metastasis. World J Surg 28 (2004) 263-270
39. Lonneux M., Reffad A.M., Detry R., Kartheuser A., Gigot J.F., and Pauwels S. FDG-PET improves the staging and selection of patients with recurrent colorectal cancer. Eur J Nucl Med Mol Imaging 29 (2002) 915-921
40. Kaim A.H., and von Schulthess G.K. [Combined functional and morphological imaging with PET/CT systems]. Schweiz Rundsch Med Prax 92 (2003) 225-227
41. Townsend D.W., Carney J.P., Yap J.T., and Hall N.C. PET/CT today and tomorrow. J Nucl Med 45 Suppl. 1 (2004) 4S-14S
42. Pelosi E., Messa C., Sironi S., et al. Value of integrated PET/CT for lesion localisation in cancer patients: a comparative study. Eur J Nucl Med Mol Imaging 31 (2004) 932-939
43. Kinahan P.E., Hasegawa B.H., and Beyer T. X-ray-based attenuation correction for positron emission tomography/computed tomography scanners. Semin Nucl Med 33 (2003) 166-179
44. Veit P., Antoch G., Stergar H., Bockisch A., Forsting M., and Kuehl H. Detection of residual tumor after radiofrequency ablation of liver metastasis with dual-modality PET/CT: initial results. Eur Radiol 16 (2006) 80-87
45. Jerusalem G., Beguin Y., Fassotte M.F., et al. Whole-body positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging. Blood 94 (1999) 429-433
46. Anderson G.S., Brinkmann F., Soulen M.C., Alavi A., and Zhuang H. FDG positron emission tomography in the surveillance of hepatic tumors treated with radiofrequency ablation. Clin Nucl Med 28 (2003) 192-197
47. Khan S., Tan Y.M., John A., et al. An audit of fusion CT-PET in the management of colorectal liver metastases. Eur J Surg Oncol 32 (2006) 564-567
48. Selzner M., Hany T.F., Wildbrett P., McCormack M., Kadry Z., and Clavien P.A. Does the novel PET/CT imaging modality impact on the treatment of patients with metastatic colorectal cancer of the liver?. Ann Surg 240 (2004) 1027-1034 discussion 1035-1026
49. Cady B., Jenkins R.L., Steele Jr. G.D., et al. Surgical margin in hepatic resection for colorectal metastasis: a critical and improvable determinant of outcome. Ann Surg 227 (1998) 566-571
50. Kato T., Yasui K., Hirai T., et al. Therapeutic results for hepatic metastasis of colorectal cancer with special reference to effectiveness of hepatectomy: analysis of prognostic factors for 763 cases recorded at 18 institutions. Dis Colon Rectum 46 (2003) S22-S31
51. Gayowski T.J., Iwatsuki S., Madariaga J.R., et al. Experience in hepatic resection for metastatic colorectal cancer: analysis of clinical and pathologic risk factors. Surgery 116 (1994) 703-710
52. Minagawa M., Makuuchi M., Torzilli G., et al. Extension of the frontiers of surgical indications in the treatment of liver metastases from colorectal cancer: long-term results. Ann Surg 231 (2000) 487-499